Transcatheter aortic valve replacement may be the better choice for high-risk patients, according to research presented at the American College of Cardiology Scientific Session. High-risk patients who underwent TAVR with Medtronic's CoreValve system experienced lower mortality than those treated with open-heart surgery, according to the study, which "further tilts the balance toward TAVR in high-risk patients," according to SCAI fellow Dr. Ajay Kirtane. A second study that compared the Sapien XT and CoreValve systems generated considerable debate at the meeting.

Related Summaries